Exclusive Summary

• - Patent barriers have expired globally and the 200 mg IV is registered in the US and EU, enabling fast multi-country entry via reliance pathways.
• - Strong hospital demand anchored in invasive aspergillosis (≈250–300k cases/year), with WHO EML listing and first-line guideline status in US/EU.
• - Significant cost advantage versus originator and newer azoles (isavuconazole/posaconazole), reducing ICU/hemato-oncology antifungal spend.
• - Despite many generics, US+EU registration and reliable supply offer differentiation for tenders and shortage back-up supply.
• - Distribution-only model fits partners with hospital channels and tender capability, accelerating launch and cash conversion.